Giandomenico D. M.
- Country
- Italy
- Department
- Oncologia medica ed Ematologia
Research Overview
- Study of Inavolisib with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2‑Positive PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
- Phase III Randomized Study of Camizestrant and CDK4/6 Inhibitor Versus Aromatase Inhibitor and CDK4/6 Inhibitor in HR+/HER2- Advanced Breast Cancer with ESR1 Mutation
- Phase III Randomized Trial of Adjuvant Avelumab in High-Risk Triple Negative Breast Cancer Post-Curative Treatment
Data & Insights
Has run more than one trial at 23 of 197 partner sites.
Specializations
Breast Cancer Specialization
This investigator demonstrates significant expertise in treating advanced breast cancer, with particular focus on hormone receptor-positive and HER2-negative disease states.
- Metastatic Breast Cancer Management
- Hormone Receptor-Positive Disease
- Triple Negative Breast Cancer
The investigator's work encompasses comprehensive treatment approaches for various breast cancer subtypes.
Therapeutic Approaches
The investigator specializes in implementing targeted therapeutic strategies, including novel combinations of endocrine therapy and innovative treatment modalities.
- CDK4/6 Inhibition Therapy
- Immunotherapy Applications
- Adjuvant Treatment Strategies
Their work involves both established and emerging therapeutic approaches in breast cancer treatment.
Treatment Innovation
The investigator focuses on precision medicine approaches in breast cancer treatment, including research into molecular targeted therapies and immunotherapeutic agents.
- ESR1 Mutation Analysis
- PD-L1 Targeted Therapy
- Neoadjuvant Treatment Approaches
Their research encompasses both early-stage and advanced disease management strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.